<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571519</url>
  </required_header>
  <id_info>
    <org_study_id>CS0011-A-U302</org_study_id>
    <nct_id>NCT00571519</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Double-blind, Placebo, and Active Comparator-controlled, Parallel-group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 26-week, multicenter, randomized, double-blind, placebo and active&#xD;
      comparator-controlled, parallel-group study in participants with type 2 diabetes currently&#xD;
      sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic&#xD;
      monotherapy. Pioglitazone is used as active comparator. The total duration of a participant's&#xD;
      participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a&#xD;
      26-week double-blind treatment period, and a 2-week post-treatment follow-up period.&#xD;
      Participants who complete the randomized portion of the study per protocol may have the&#xD;
      opportunity to continue in a long-term extension study of active treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    DSPD focusing on Study 301 to confirm the clinical profile before proceeding. Daiichi Sankyo&#xD;
    Pharma Development terminated this study on 23 Apr 2008 because of changes in the clinical&#xD;
    development plan with 94 of 2600 planned, randomized participants.&#xD;
  </why_stopped>
  <start_date type="Actual">November 14, 2007</start_date>
  <completion_date type="Actual">May 23, 2008</completion_date>
  <primary_completion_date type="Actual">May 23, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 2, week 4, week 6, week 8, week 10, week 12, week 16, and week 20 post-dose.</time_frame>
    <description>Glycosylated hemoglobin (A1c) levels and mean changes in A1c were used to measure glycemic control. A1c categorical targets are &lt;7.0% and &lt;6.5%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 2, week 4, week 6, week 8, week 12, week 16, and week 20 post-dose.</time_frame>
    <description>Normal fasting plasma glucose (FPG) -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline and a lower FPG means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Low-density lipoprotein cholesterol (LDL-C) is a measure of the total amount of low-density lipoprotein cholesterol in the blood. LDL-C was measured as part of the fasting lipid panel. LDL-C is considered &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Low-density lipoprotein cholesterol (LDL-C) is a measure of the total amount of low-density lipoprotein cholesterol in the blood. LDL-C was measured as part of the fasting lipid panel. LDL-C is considered &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>High-density lipoprotein cholesterol (HDL-C) is a measure of the total amount of high-density lipoprotein cholesterol in the blood. HDL-C was measured as part of the fasting lipid panel. HDL-C is considered &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>High-density lipoprotein cholesterol (HDL-C) is a measure of the total amount of high-density lipoprotein cholesterol in the blood. HDL-C was measured as part of the fasting lipid panel. HDL-C is considered &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Apo A-I was measured as part of the fasting lipid panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Apo A-I was measured as part of the fasting lipid panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Apolipoprotein (Apo) B is a measure of the total amount of Apolipoprotein (Apo) B in the blood. Apo B was measured as part of the fasting lipid panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 12 post-dose.</time_frame>
    <description>Apolipoprotein (Apo) B is a measure of the total amount of Apolipoprotein (Apo) B in the blood. Apo B was measured as part of the fasting lipid panel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</measure>
    <time_frame>Baseline up to week 26 post-dose, approximately a total of 27 weeks.</time_frame>
    <description>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of randomized study medication and ongoing adverse events that started prior to the first dose of randomized study medication and increased in severity on or after the first dose of randomized study medication.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivoglitazone HCl 0.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivoglitazone HCl 1.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rivoglitazone HCl 1.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo matching rivoglitazone HCl tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone HCl 15 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone HCl 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pioglitazone HCl 45 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo for pioglitazone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivoglitazone HCl</intervention_name>
    <description>0.5 mg tablets administered orally, once daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CS-011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivoglitazone HCl</intervention_name>
    <description>1.0 mg tablets administered orally, once daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>CS-011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivoglitazone HCl</intervention_name>
    <description>1.5 mg tablets administered orally, once daily</description>
    <arm_group_label>3</arm_group_label>
    <other_name>CS-011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets matching rivoglitazone tablets administered orally, once daily</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone HCl</intervention_name>
    <description>15 mg capsules administered orally, once daily</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone HCl</intervention_name>
    <description>30 mg capsules administered orally, once daily</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone HCl 45 mg</intervention_name>
    <description>45 mg capsules administered orally, once daily</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsules for pioglitazone administered orally, once daily</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Oral tablets. Rescue medication.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provided written informed consent at screening.&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes mellitus.&#xD;
&#xD;
          -  Glycosylated hemoglobin (A1c) &gt;7.0% and ≤8.5% at screening.&#xD;
&#xD;
          -  Male or female ≥18 years of age.&#xD;
&#xD;
          -  Women of childbearing potential must have been using an adequate method of&#xD;
             contraception to avoid pregnancy throughout the study, and for up to 4 weeks after&#xD;
             study completion.&#xD;
&#xD;
          -  Fasting C-peptide level &gt;0.5 ng/mL at screening.&#xD;
&#xD;
          -  Currently being treated with a stable dose of an approved non-thiazolidinedione&#xD;
             antihyperglycemic medication (including sulfonylureas, meglitinides, insulin&#xD;
             secretagogues, metformin, or α-glucosidase inhibitors) given as monotherapy, for at&#xD;
             least 3 months prior to screening, and could discontinue that antihyperglycemic&#xD;
             medication at Visit 2 (Week -2) and for the duration of the study. OR&#xD;
&#xD;
          -  Untreated and had not taken any antihyperglycemic agent during the 2 months prior to&#xD;
             screening; if not treated with an oral antihyperglycemic agent, the participant was&#xD;
             considered by the investigator to have failed diet and exercise modification as the&#xD;
             sole treatment for type 2 diabetes mellitus.&#xD;
&#xD;
          -  Clinically stable in regard to medical conditions other than type 2 diabetes mellitus.&#xD;
&#xD;
          -  Concomitant medications (other than oral antihyperglycemic agents) were at stable&#xD;
             doses for at least 30 days prior to enrollment and were not anticipated to need&#xD;
             adjustment during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes and/or history of ketoacidosis.&#xD;
&#xD;
          -  History of long-term (&gt;2 months) therapy with insulin.&#xD;
&#xD;
          -  History of prior treatment failure with, or intolerance of, a thiazolidinedione (ie,&#xD;
             rosiglitazone, troglitazone, or pioglitazone).&#xD;
&#xD;
          -  Treatment with a fibrate lipid-lowering agent (eg, fenofibrate, gemfibrozil).&#xD;
&#xD;
          -  Confirmed repeat fasting glucose (≥2 readings of fasting blood glucose) &gt;240 mg/dL&#xD;
             (13.3 mmol/L) during the 2-week washout/stabilization and placebo run-in period&#xD;
             (Period A).&#xD;
&#xD;
          -  Body mass index (BMI) &gt;45 kg/m2 at screening.&#xD;
&#xD;
          -  History of weight loss &gt;10% over the 3 months prior to screening.&#xD;
&#xD;
          -  Female participant who was pregnant or breastfeeding.&#xD;
&#xD;
          -  Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure&#xD;
&#xD;
             ≥110 mmHg.&#xD;
&#xD;
          -  Any known history of congestive heart failure prior to screening.&#xD;
&#xD;
          -  History of unstable angina, myocardial infarction, cerebrovascular accident, transient&#xD;
             ischemic attack, or any revascularization within 6 months prior to screening. History&#xD;
             of malignancy (except participants who had been disease-free for &gt;10 years), or whose&#xD;
             malignancy was a basal or squamous cell skin carcinoma. Any history of bladder cancer&#xD;
             was an exclusion from participation. Women with a history of cervical dysplasia (CIN2&#xD;
             or higher) were to be excluded unless 2 consecutive normal cervical smears had&#xD;
             subsequently been recorded prior to enrollment.&#xD;
&#xD;
          -  Impaired liver function including evidence of acute or chronic hepatitis or liver&#xD;
             disease by medical history, clinical signs or symptoms, or laboratory results.&#xD;
&#xD;
          -  Evidence for ongoing infectious liver disease with positive hepatitis A antigen or&#xD;
             immunoglobulin M antibody, hepatitis B surface antigen, or antibodies to hepatitis C&#xD;
             virus. Participants with normal liver function tests and isolated positive antibodies&#xD;
             to hepatitis B virus could have been included.&#xD;
&#xD;
          -  Known (or evidence of) infection with human immunodeficiency virus.&#xD;
&#xD;
          -  Known hemoglobinopathy or chronic anemia that required specific treatment within 5&#xD;
             years of the screening visit.&#xD;
&#xD;
          -  History of alcohol or drug abuse within 1 year prior to screening.&#xD;
&#xD;
          -  History of unstable major psychiatric disorders. Known or suspected allergy or&#xD;
             hypersensitivity to thiazolidinedione agents.&#xD;
&#xD;
          -  Clinically significant abnormalities in any pre-randomization laboratory analyses&#xD;
             that, in the investigator's opinion, comprised an undue risk with the participant's&#xD;
             participation, or could potentially confound results of the study.&#xD;
&#xD;
        Unexplained hematuria (&gt;3 red blood cells per high-powered field by urine microscopy).&#xD;
&#xD;
          -  Blood donation of ≥1 pint (0.5 liter) within the past 30 days prior to screening or&#xD;
             plasma donation within 7 days prior to the screening visit (Visit 1).&#xD;
&#xD;
          -  Prior known or possible exposure to rivoglitazone.&#xD;
&#xD;
          -  Contraindication to treatment with pioglitazone once daily.&#xD;
&#xD;
          -  Known or suspected allergy, hypersensitivity, or intolerance to the excipients of the&#xD;
             investigational study medication.&#xD;
&#xD;
          -  Participation in an interventional medical, surgical, or pharmaceutical study within&#xD;
             30 days prior to the screening visit (Visit 1).&#xD;
&#xD;
          -  Any condition or concomitant therapy that, in the opinion of the investigator, might&#xD;
             have posed a risk to the participant or made participation not in the participant's&#xD;
             best interest.&#xD;
&#xD;
          -  A direct or familial relationship with the Sponsor, investigator, or site personnel&#xD;
             affiliated with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <zip>06877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Gibson</city>
        <state>Mississippi</state>
        <zip>39150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <zip>19522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daingerfield</city>
        <state>Texas</state>
        <zip>75638</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>February 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <disposition_first_submitted>February 1, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 1, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 5, 2013</disposition_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 94 participants who met all inclusion criteria and no exclusion criteria were enrolled in the study at 73 clinic sites in the United States of America and 22 in India.</recruitment_details>
      <pre_assignment_details>Participants with type 2 diabetes mellitus who were either untreated (ie, not receiving antihyperglycemic medication within at least 2 months prior to screening) or were treated with a single, non-thiazolidinedione agent as monotherapy without adequate glycemic control were enrolled in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Rivoglitazone 0.5mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Rivoglitazone 1.0mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Rivoglitazone 1.5mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Pioglitazone 15 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Pioglitazone 30 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Pioglitazone 45 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemia meeting discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Therapeutic failure/lack of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Termination of study by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Per medical monitor regarding thyroid-stimulating hormone level</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were assessed from the All Randomized Set.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Rivoglitazone 0.5mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Rivoglitazone 1.0mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Rivoglitazone 1.5mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Pioglitazone 15 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Pioglitazone 30 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Pioglitazone 45 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="10"/>
            <count group_id="B7" value="24"/>
            <count group_id="B8" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.0" spread="11.36"/>
                    <measurement group_id="B2" value="55.1" spread="13.03"/>
                    <measurement group_id="B3" value="58.3" spread="10.86"/>
                    <measurement group_id="B4" value="59.4" spread="10.46"/>
                    <measurement group_id="B5" value="57.0" spread="9.85"/>
                    <measurement group_id="B6" value="58.5" spread="7.71"/>
                    <measurement group_id="B7" value="58.0" spread="11.72"/>
                    <measurement group_id="B8" value="58.1" spread="10.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Glycosylated hemoglobin (A1c) levels and mean changes in A1c were used to measure glycemic control. A1c categorical targets are &lt;7.0% and &lt;6.5%.</description>
        <time_frame>Baseline up to week 2, week 4, week 6, week 8, week 10, week 12, week 16, and week 20 post-dose.</time_frame>
        <population>Change in A1c was assessed using the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Glycosylated hemoglobin (A1c) levels and mean changes in A1c were used to measure glycemic control. A1c categorical targets are &lt;7.0% and &lt;6.5%.</description>
          <population>Change in A1c was assessed using the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>percentage of A1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="0.55"/>
                    <measurement group_id="O2" value="7.5" spread="0.41"/>
                    <measurement group_id="O3" value="7.7" spread="0.67"/>
                    <measurement group_id="O4" value="7.5" spread="0.46"/>
                    <measurement group_id="O5" value="7.7" spread="0.56"/>
                    <measurement group_id="O6" value="7.5" spread="0.51"/>
                    <measurement group_id="O7" value="7.6" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="0.87"/>
                    <measurement group_id="O2" value="7.6" spread="0.54"/>
                    <measurement group_id="O3" value="7.9" spread="0.96"/>
                    <measurement group_id="O4" value="7.6" spread="0.49"/>
                    <measurement group_id="O5" value="7.6" spread="0.61"/>
                    <measurement group_id="O6" value="7.5" spread="0.43"/>
                    <measurement group_id="O7" value="7.7" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Baseline to Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="23"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.67"/>
                    <measurement group_id="O2" value="0.1" spread="0.23"/>
                    <measurement group_id="O3" value="0.1" spread="0.54"/>
                    <measurement group_id="O4" value="0.1" spread="0.30"/>
                    <measurement group_id="O5" value="-0.1" spread="0.23"/>
                    <measurement group_id="O6" value="0.1" spread="0.19"/>
                    <measurement group_id="O7" value="0.1" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="1.06"/>
                    <measurement group_id="O2" value="7.6" spread="0.86"/>
                    <measurement group_id="O3" value="7.4" spread="0.42"/>
                    <measurement group_id="O4" value="7.5" spread="0.56"/>
                    <measurement group_id="O5" value="7.6" spread="0.68"/>
                    <measurement group_id="O6" value="7.4" spread="0.56"/>
                    <measurement group_id="O7" value="7.6" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.28"/>
                    <measurement group_id="O2" value="0.2" spread="0.49"/>
                    <measurement group_id="O3" value="-0.1" spread="0.32"/>
                    <measurement group_id="O4" value="-0.0" spread="0.43"/>
                    <measurement group_id="O5" value="-0.0" spread="0.32"/>
                    <measurement group_id="O6" value="-0.1" spread="0.27"/>
                    <measurement group_id="O7" value="-0.0" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O2" value="7.7" spread="0.99"/>
                    <measurement group_id="O3" value="7.4" spread="0.39"/>
                    <measurement group_id="O4" value="7.3" spread="0.55"/>
                    <measurement group_id="O5" value="7.4" spread="0.68"/>
                    <measurement group_id="O6" value="7.2" spread="0.65"/>
                    <measurement group_id="O7" value="7.5" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O2" value="0.3" spread="0.61"/>
                    <measurement group_id="O3" value="-0.2" spread="0.25"/>
                    <measurement group_id="O4" value="-0.1" spread="0.41"/>
                    <measurement group_id="O5" value="-0.2" spread="0.18"/>
                    <measurement group_id="O6" value="-0.2" spread="0.46"/>
                    <measurement group_id="O7" value="-0.2" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.2" spread="0.62"/>
                    <measurement group_id="O3" value="7.4" spread="0.23"/>
                    <measurement group_id="O4" value="7.2" spread="0.52"/>
                    <measurement group_id="O5" value="7.6" spread="0.76"/>
                    <measurement group_id="O6" value="7.2" spread="0.54"/>
                    <measurement group_id="O7" value="7.4" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="0.48"/>
                    <measurement group_id="O3" value="-0.5" spread="0.53"/>
                    <measurement group_id="O4" value="-0.2" spread="0.37"/>
                    <measurement group_id="O5" value="0.0" spread="0.78"/>
                    <measurement group_id="O6" value="-0.2" spread="0.42"/>
                    <measurement group_id="O7" value="-0.3" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.2" spread="0.92"/>
                    <measurement group_id="O3" value="7.2" spread="0.00"/>
                    <measurement group_id="O4" value="7.2" spread="0.40"/>
                    <measurement group_id="O5" value="7.6" spread="0.71"/>
                    <measurement group_id="O6" value="6.8" spread="0.70"/>
                    <measurement group_id="O7" value="7.2" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="1.13"/>
                    <measurement group_id="O3" value="-0.7" spread="0.28"/>
                    <measurement group_id="O4" value="-0.3" spread="0.37"/>
                    <measurement group_id="O5" value="-0.2" spread="0.27"/>
                    <measurement group_id="O6" value="-0.4" spread="0.76"/>
                    <measurement group_id="O7" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.7" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="7.2" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="7.0" spread="0.54"/>
                    <measurement group_id="O5" value="7.2" spread="0.44"/>
                    <measurement group_id="O6" value="7.0" spread="0.39"/>
                    <measurement group_id="O7" value="7.0" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.7" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="-0.9" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="-0.2" spread="0.29"/>
                    <measurement group_id="O5" value="-0.2" spread="0.29"/>
                    <measurement group_id="O6" value="-0.1" spread="0.44"/>
                    <measurement group_id="O7" value="-0.8" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7.7" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O6" value="6.9" spread="0.00"/>
                    <measurement group_id="O7" value="7.4" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.7" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O6" value="-0.4" spread="0.35"/>
                    <measurement group_id="O7" value="-0.8" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="7.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O7" value="7.4" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="-0.6" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O7" value="-0.6" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Normal fasting plasma glucose (FPG) -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline and a lower FPG means improvement.</description>
        <time_frame>Baseline up to week 2, week 4, week 6, week 8, week 12, week 16, and week 20 post-dose.</time_frame>
        <population>Fasting Plasma Glucose was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Normal fasting plasma glucose (FPG) -- or blood sugar -- is between 70 and 100 milligrams per deciliter (mg/dL) for people who do not have diabetes. People with Type 2 diabetes typically have FPG that is too high, so a negative change from baseline and a lower FPG means improvement.</description>
          <population>Fasting Plasma Glucose was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.7" spread="48.09"/>
                    <measurement group_id="O2" value="164.1" spread="45.09"/>
                    <measurement group_id="O3" value="160.1" spread="34.34"/>
                    <measurement group_id="O4" value="162.2" spread="42.37"/>
                    <measurement group_id="O5" value="173.3" spread="35.77"/>
                    <measurement group_id="O6" value="138.3" spread="22.89"/>
                    <measurement group_id="O7" value="158.5" spread="35.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.0" spread="71.51"/>
                    <measurement group_id="O2" value="157.8" spread="48.45"/>
                    <measurement group_id="O3" value="149.8" spread="49.38"/>
                    <measurement group_id="O4" value="152.4" spread="50.06"/>
                    <measurement group_id="O5" value="160.8" spread="21.12"/>
                    <measurement group_id="O6" value="140.9" spread="19.43"/>
                    <measurement group_id="O7" value="144.7" spread="34.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="41.59"/>
                    <measurement group_id="O2" value="-1.0" spread="20.06"/>
                    <measurement group_id="O3" value="-10.5" spread="36.05"/>
                    <measurement group_id="O4" value="-13.6" spread="33.75"/>
                    <measurement group_id="O5" value="-12.5" spread="22.48"/>
                    <measurement group_id="O6" value="2.6" spread="16.93"/>
                    <measurement group_id="O7" value="-13.8" spread="24.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.5" spread="37.48"/>
                    <measurement group_id="O2" value="149.4" spread="55.44"/>
                    <measurement group_id="O3" value="128.6" spread="33.31"/>
                    <measurement group_id="O4" value="145.6" spread="35.32"/>
                    <measurement group_id="O5" value="171.4" spread="48.23"/>
                    <measurement group_id="O6" value="140.3" spread="30.49"/>
                    <measurement group_id="O7" value="143.6" spread="26.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="21"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.5" spread="43.13"/>
                    <measurement group_id="O2" value="-8.3" spread="12.50"/>
                    <measurement group_id="O3" value="-24.6" spread="30.97"/>
                    <measurement group_id="O4" value="-26.2" spread="27.69"/>
                    <measurement group_id="O5" value="-1.9" spread="38.79"/>
                    <measurement group_id="O6" value="2.3" spread="20.34"/>
                    <measurement group_id="O7" value="-20.0" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O2" value="158.4" spread="54.77"/>
                    <measurement group_id="O3" value="126.5" spread="24.14"/>
                    <measurement group_id="O4" value="126.9" spread="17.76"/>
                    <measurement group_id="O5" value="174.3" spread="41.80"/>
                    <measurement group_id="O6" value="134.0" spread="25.00"/>
                    <measurement group_id="O7" value="146.8" spread="44.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O2" value="-0.2" spread="23.70"/>
                    <measurement group_id="O3" value="-30.8" spread="22.22"/>
                    <measurement group_id="O4" value="-41.1" spread="33.09"/>
                    <measurement group_id="O5" value="0.7" spread="48.65"/>
                    <measurement group_id="O6" value="-4.0" spread="12.51"/>
                    <measurement group_id="O7" value="-17.1" spread="41.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="153.6" spread="56.44"/>
                    <measurement group_id="O3" value="129.5" spread="15.35"/>
                    <measurement group_id="O4" value="125.0" spread="15.70"/>
                    <measurement group_id="O5" value="149.2" spread="35.72"/>
                    <measurement group_id="O6" value="145.6" spread="49.47"/>
                    <measurement group_id="O7" value="148.3" spread="34.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="12.2" spread="32.89"/>
                    <measurement group_id="O3" value="-41.3" spread="26.29"/>
                    <measurement group_id="O4" value="-35.1" spread="20.51"/>
                    <measurement group_id="O5" value="-23.2" spread="57.14"/>
                    <measurement group_id="O6" value="7.6" spread="41.71"/>
                    <measurement group_id="O7" value="-20.0" spread="28.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="142.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="131.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="120.3" spread="11.79"/>
                    <measurement group_id="O5" value="131.7" spread="13.43"/>
                    <measurement group_id="O6" value="122.3" spread="13.23"/>
                    <measurement group_id="O7" value="126.4" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="16.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="-51.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="-32.5" spread="25.38"/>
                    <measurement group_id="O5" value="-25.3" spread="18.58"/>
                    <measurement group_id="O6" value="-9.8" spread="25.08"/>
                    <measurement group_id="O7" value="-29.4" spread="20.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="159.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O6" value="111.0" spread="2.83"/>
                    <measurement group_id="O7" value="133.7" spread="22.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="2"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="33.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O6" value="-19.5" spread="4.95"/>
                    <measurement group_id="O7" value="-39.3" spread="51.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="107.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O7" value="124.0" spread="15.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="-25.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O7" value="-18.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Total cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
          <population>Total cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.2" spread="38.10"/>
                    <measurement group_id="O2" value="211.3" spread="52.87"/>
                    <measurement group_id="O3" value="204.9" spread="63.66"/>
                    <measurement group_id="O4" value="171.6" spread="38.95"/>
                    <measurement group_id="O5" value="172.1" spread="35.49"/>
                    <measurement group_id="O6" value="201.7" spread="50.13"/>
                    <measurement group_id="O7" value="188.1" spread="47.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="311.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="193.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="145.8" spread="17.27"/>
                    <measurement group_id="O5" value="151.3" spread="47.08"/>
                    <measurement group_id="O6" value="213.3" spread="28.62"/>
                    <measurement group_id="O7" value="186.6" spread="36.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Total cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total cholesterol is a measure of the total amount of cholesterol in the blood, including low-density lipoprotein cholesterol (LDL-C) - the &quot;bad&quot; cholesterol, high-density lipoprotein cholesterol (HDL-C) - the &quot;good&quot; cholesterol, and triglycerides. The equation to calculate total cholesterol is: LDL + HDL + (triglycerides/5) = total cholesterol.</description>
          <population>Total cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8.9" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="-8.5" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="-2.2" spread="6.46"/>
                    <measurement group_id="O5" value="-1.6" spread="9.54"/>
                    <measurement group_id="O6" value="2.7" spread="15.73"/>
                    <measurement group_id="O7" value="7.4" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means improvement.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Total Triglycerides were assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means improvement.</description>
          <population>Total Triglycerides were assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.8" spread="15.94"/>
                    <measurement group_id="O2" value="293.2" spread="300.50"/>
                    <measurement group_id="O3" value="214.8" spread="145.63"/>
                    <measurement group_id="O4" value="156.5" spread="85.96"/>
                    <measurement group_id="O5" value="165.7" spread="118.31"/>
                    <measurement group_id="O6" value="221.0" spread="188.82"/>
                    <measurement group_id="O7" value="163.0" spread="72.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="179.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="180.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="72.0" spread="6.73"/>
                    <measurement group_id="O5" value="82.3" spread="44.52"/>
                    <measurement group_id="O6" value="161.3" spread="100.69"/>
                    <measurement group_id="O7" value="90.8" spread="41.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means improvement.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Total Triglycerides were assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Triglycerides From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Total Triglycerides (TG) is a measure of the total amount of triglycerides in the blood. The equation to calculate total triglycerides is: (total cholesterol-Low-density Lipoprotein cholesterol (LDL- C) - High-density lipoprotein cholesterol (HDL- C)) x 5 = Total Triglycerides. A negative change means improvement.</description>
          <population>Total Triglycerides were assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-15.4" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="-34.1" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="-16.8" spread="16.17"/>
                    <measurement group_id="O5" value="-20.5" spread="40.04"/>
                    <measurement group_id="O6" value="-16.1" spread="24.80"/>
                    <measurement group_id="O7" value="-16.2" spread="33.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Low-density lipoprotein cholesterol (LDL-C) is a measure of the total amount of low-density lipoprotein cholesterol in the blood. LDL-C was measured as part of the fasting lipid panel. LDL-C is considered &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Low-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Low-density lipoprotein cholesterol (LDL-C) is a measure of the total amount of low-density lipoprotein cholesterol in the blood. LDL-C was measured as part of the fasting lipid panel. LDL-C is considered &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
          <population>Low-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.7" spread="33.90"/>
                    <measurement group_id="O2" value="124.1" spread="45.67"/>
                    <measurement group_id="O3" value="125.8" spread="53.79"/>
                    <measurement group_id="O4" value="95.9" spread="28.52"/>
                    <measurement group_id="O5" value="95.7" spread="22.73"/>
                    <measurement group_id="O6" value="105.8" spread="35.12"/>
                    <measurement group_id="O7" value="108.4" spread="41.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="226.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="112.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="78.5" spread="20.70"/>
                    <measurement group_id="O5" value="82.7" spread="45.54"/>
                    <measurement group_id="O6" value="129.8" spread="10.56"/>
                    <measurement group_id="O7" value="111.6" spread="24.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Low-density lipoprotein cholesterol (LDL-C) is a measure of the total amount of low-density lipoprotein cholesterol in the blood. LDL-C was measured as part of the fasting lipid panel. LDL-C is considered &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Low-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Low-density lipoprotein cholesterol (LDL-C) is a measure of the total amount of low-density lipoprotein cholesterol in the blood. LDL-C was measured as part of the fasting lipid panel. LDL-C is considered &quot;bad&quot; cholesterol, so a lower score (negative change) means improvement.</description>
          <population>Low-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="16.8" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="-1.8" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="-8.6" spread="3.25"/>
                    <measurement group_id="O5" value="-5.7" spread="18.70"/>
                    <measurement group_id="O6" value="14.5" spread="1.15"/>
                    <measurement group_id="O7" value="14.0" spread="18.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>High-density lipoprotein cholesterol (HDL-C) is a measure of the total amount of high-density lipoprotein cholesterol in the blood. HDL-C was measured as part of the fasting lipid panel. HDL-C is considered &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>High-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>High-density lipoprotein cholesterol (HDL-C) is a measure of the total amount of high-density lipoprotein cholesterol in the blood. HDL-C was measured as part of the fasting lipid panel. HDL-C is considered &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
          <population>High-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" spread="2.31"/>
                    <measurement group_id="O2" value="43.9" spread="10.84"/>
                    <measurement group_id="O3" value="42.4" spread="9.23"/>
                    <measurement group_id="O4" value="44.3" spread="13.70"/>
                    <measurement group_id="O5" value="42.5" spread="10.87"/>
                    <measurement group_id="O6" value="49.4" spread="14.23"/>
                    <measurement group_id="O7" value="47.2" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="49.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="45.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="52.8" spread="11.53"/>
                    <measurement group_id="O5" value="52.3" spread="21.01"/>
                    <measurement group_id="O6" value="51.3" spread="10.14"/>
                    <measurement group_id="O7" value="56.6" spread="14.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="5.9" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="13.1" spread="14.03"/>
                    <measurement group_id="O5" value="12.9" spread="12.93"/>
                    <measurement group_id="O6" value="10.8" spread="10.26"/>
                    <measurement group_id="O7" value="11.1" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>High-density lipoprotein cholesterol (HDL-C) is a measure of the total amount of high-density lipoprotein cholesterol in the blood. HDL-C was measured as part of the fasting lipid panel. HDL-C is considered &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>High-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-Density Lipoprotein Cholesterol From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>High-density lipoprotein cholesterol (HDL-C) is a measure of the total amount of high-density lipoprotein cholesterol in the blood. HDL-C was measured as part of the fasting lipid panel. HDL-C is considered &quot;good&quot; cholesterol, so a higher score (positive change) means improvement.</description>
          <population>High-Density Lipoprotein Cholesterol was assessed from the Full Analysis Set. There were &quot;0&quot; numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination so cannot be included in the table.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-1.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="5.9" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="13.1" spread="14.03"/>
                    <measurement group_id="O5" value="12.9" spread="12.93"/>
                    <measurement group_id="O6" value="10.8" spread="10.26"/>
                    <measurement group_id="O7" value="11.1" spread="10.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Apo A-I was measured as part of the fasting lipid panel.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Apolipoprotein (Apo) A-I was assessed from the Full Analysis Set. There were instances of zero (0) numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination and were not reported in the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Apo A-I was measured as part of the fasting lipid panel.</description>
          <population>Apolipoprotein (Apo) A-I was assessed from the Full Analysis Set. There were instances of zero (0) numbers analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data was not collected for participants that did not complete the later time points prior to study termination and were not reported in the table.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.0" spread="7.57"/>
                    <measurement group_id="O2" value="146.7" spread="15.68"/>
                    <measurement group_id="O3" value="139.7" spread="16.20"/>
                    <measurement group_id="O4" value="142.4" spread="27.72"/>
                    <measurement group_id="O5" value="133.0" spread="20.34"/>
                    <measurement group_id="O6" value="158.6" spread="31.57"/>
                    <measurement group_id="O7" value="149.6" spread="25.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="144.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="141.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="149.8" spread="21.08"/>
                    <measurement group_id="O5" value="145.3" spread="34.27"/>
                    <measurement group_id="O6" value="153.0" spread="24.14"/>
                    <measurement group_id="O7" value="158.2" spread="31.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Apo A-I was measured as part of the fasting lipid panel.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Apolipoprotein (Apo) A-I was assessed from the Full Analysis Set. There were instances of zero (0) number analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data were not collected for participants that did not complete the later time points prior to study termination and not available for the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein (Apo) A-I From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) A-I is a measure of the total amount of Apolipoprotein (Apo) A-I in the blood. Apo A-I was measured as part of the fasting lipid panel.</description>
          <population>Apolipoprotein (Apo) A-I was assessed from the Full Analysis Set. There were instances of zero (0) number analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data were not collected for participants that did not complete the later time points prior to study termination and not available for the table.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-14.5" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="-2.8" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="2.8" spread="9.18"/>
                    <measurement group_id="O5" value="3.0" spread="6.90"/>
                    <measurement group_id="O6" value="0.3" spread="6.81"/>
                    <measurement group_id="O7" value="1.4" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) B is a measure of the total amount of Apolipoprotein (Apo) B in the blood. Apo B was measured as part of the fasting lipid panel.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Apolipoprotein (Apo) B was assessed from the Full Analysis Set. There were instances of zero (0) number analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data were not collected for participants that did not complete the later time points prior to study termination and not available for the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) B is a measure of the total amount of Apolipoprotein (Apo) B in the blood. Apo B was measured as part of the fasting lipid panel.</description>
          <population>Apolipoprotein (Apo) B was assessed from the Full Analysis Set. There were instances of zero (0) number analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data were not collected for participants that did not complete the later time points prior to study termination and not available for the table.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" spread="26.44"/>
                    <measurement group_id="O2" value="119.1" spread="36.53"/>
                    <measurement group_id="O3" value="121.9" spread="36.37"/>
                    <measurement group_id="O4" value="101.3" spread="29.72"/>
                    <measurement group_id="O5" value="105.5" spread="34.32"/>
                    <measurement group_id="O6" value="113.4" spread="25.20"/>
                    <measurement group_id="O7" value="108.4" spread="31.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="206.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="115.0" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="76.5" spread="17.06"/>
                    <measurement group_id="O5" value="77.7" spread="31.53"/>
                    <measurement group_id="O6" value="120.8" spread="15.46"/>
                    <measurement group_id="O7" value="95.6" spread="23.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Apolipoprotein (Apo) B is a measure of the total amount of Apolipoprotein (Apo) B in the blood. Apo B was measured as part of the fasting lipid panel.</description>
        <time_frame>Baseline up to week 12 post-dose.</time_frame>
        <population>Apolipoprotein (Apo) B was assessed from the Full Analysis Set. There were instances of zero (0) number analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data were not collected for participants that did not complete the later time points prior to study termination and not available for the table.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein (Apo) B From Baseline Through Week 12 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Apolipoprotein (Apo) B is a measure of the total amount of Apolipoprotein (Apo) B in the blood. Apo B was measured as part of the fasting lipid panel.</description>
          <population>Apolipoprotein (Apo) B was assessed from the Full Analysis Set. There were instances of zero (0) number analyzed reported beyond Week 6 due to early termination by the sponsor because of changes in the clinical development plan. Data were not collected for participants that did not complete the later time points prior to study termination and not available for the table.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="13.2" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O3" value="-12.2" spread="NA">Not available as data was calculated for one participant.</measurement>
                    <measurement group_id="O4" value="-11.5" spread="5.21"/>
                    <measurement group_id="O5" value="-14.8" spread="20.97"/>
                    <measurement group_id="O6" value="0.1" spread="6.63"/>
                    <measurement group_id="O7" value="1.7" spread="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
        <description>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of randomized study medication and ongoing adverse events that started prior to the first dose of randomized study medication and increased in severity on or after the first dose of randomized study medication.</description>
        <time_frame>Baseline up to week 26 post-dose, approximately a total of 27 weeks.</time_frame>
        <population>Treatment-emergent adverse events were assessed from the Safety Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rivoglitazone 0.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rivoglitazone 1.0mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Rivoglitazone 1.5mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Pioglitazone 15 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Pioglitazone 30 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Pioglitazone 45 mg</title>
            <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events by System Organ Class and Preferred Term Following Rivoglitazone or Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus</title>
          <description>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of randomized study medication and ongoing adverse events that started prior to the first dose of randomized study medication and increased in severity on or after the first dose of randomized study medication.</description>
          <population>Treatment-emergent adverse events were assessed from the Safety Set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphadenitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypothyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular Hyperaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Mouth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flatulence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-cardiac chest pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oedema peripheral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholelithiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seasonal allergy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fungal infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Furuncle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasopharyngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral upper respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthropod bite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood creatine phosphokinase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell morphology abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flank pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint crepitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle twitching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal stiffness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carpal tunnel syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood altered</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pharyngolaryngeal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperhidrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse event (TEAE) data were collected from Baseline (Day 1) up to week 26 post-dose, approximately a total of 27 weeks.</time_frame>
      <desc>Treatment-emergent adverse events (TEAEs) were defined as adverse events (AEs) that occurred on or after the first dose of randomized study medication and ongoing adverse events that started prior to the first dose of randomized study medication and increased in severity on or after the first dose of randomized study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone-matching placebo tablet or a Pioglitazone-matching placebo capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Rivoglitazone 0.5mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 0.5mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Rivoglitazone 1.0mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.0mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Rivoglitazone 1.5mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Rivoglitazone 1.5mg tablet once daily for 18 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Pioglitazone 15 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 15 mg capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Pioglitazone 30 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 30 mg capsule once daily for 18 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Pioglitazone 45 mg</title>
          <description>Participants with type 2 diabetes mellitus who were administered a Pioglitazone 45 mg capsule once daily for 18 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Red blood cell morphology abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint crepitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Contact for Clinical Trial Information</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>908-992-6400</phone>
      <email>CTRinfo@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

